ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.
What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
Faith Over Fear, My Life Matters (Winter 2023-2024)
A journey to inclusive breast cancer care through faith, science, and personalized testing.
Read the ArticleArticle: Disparities in Survival Outcomes Revealed w/ BluePrint + MammaPrint
“These data highlight the importance of genomic testing to help optimize treatment and reduce outcome disparities in Black women.”
Read the ArticleAgendia Touting New Data Showing Pre-Surgery Use of MammaPrint, BluePrint
Research showing that Agendia's MammaPrint and BluePrint tests can predict which breast cancer patients are likely to have the cancer in their lymph nodes down-staged following neoadjuvant chemotherapy has the company optimistic about a potentially new use for its gene expression tests.
Read the ArticleFierce Healthcare: Biden’s ‘Cancer Moonshot’ is already being fueled by tech addressing breast cancer
Fierce Healthcare recently spoke with Nathalie Johnson, MD, FACS, President of The American Society of Breast Cancer Surgeons, about the need for more widespread use of advanced gene expression profiling tests that provide more consistent results for Black women with early-stage breast cancer. Dr. Johnson highlights how the standard of care today negatively impacts outcomes for Black women, and why it is essential for clinicians to switch to more sophisticated, unbiased tests, such as MammaPrint & BluePrint, to address key disparities in breast cancer care.
Read the Article
News
Media Releases
MammaPrint® approved for Reimbursement in the Netherlands
The Dutch National Healthcare Institute (ZIN) has approved MammaPrint® for inclusion in the Dutch National health insurance basic package with immediate effect.
Read MoreAgendia® Names Joyce A. O’Shaughnessy, MD as New Principal Investigator for FLEX Study
Renowned breast oncologist and clinical researcher to lead ongoing efforts to accelerate diagnostic discoveries and enable precision oncology through real-world evidence-based study platform
Read MoreNew Neoadjuvant Trial (MINT) Confirms the Predictive Utility of MammaPrint + BluePrint
The newly published prospective Multi-Institutional Neoadjuvant Therapy MammaPrint Project I (MINT) trial is the first neoadjuvant study to show that nodal downstaging in response to neoadjuvant therapy can be predicted by MammaPrint + BluePrint, Agendia’s advanced genomic assays.
Read MoreAgendia Appoints Ronald Andrews and David Schreiber to Board of Directors
Agendia, Inc., a gene expression profiling company advancing personalized early-stage breast cancer care, today announced the appointment of industry veterans Ronald (Ron) Andrews and David Schreiber to the company’s Board of Directors.
Read More
